Sitemap > Breaking Research > Cardiovascular Disorders
Displaying 1251 - 1300 of 4862 results
- Annexin A3 is a potential angiogenic mediator.
- MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice.
- Roles of cyclooxygenase-2 and prostacyclin/IP receptors in mucosal defense against ischemia/reperfusion injury in mouse stomach.
- Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
- Left atrial dysfunction in patients with atrial fibrillation after successful rhythm control for > 3 months.
- Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction.
- Increased prevalence of third-degree atrioventricular block in patients with type II diabetes mellitus.
- Pivotal role of NOX-2-containing NADPH oxidase in early ischemic preconditioning.
- Erectile dysfunction as a marker for vascular disease.
- Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: association and management.
- Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system.
- Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation.
- Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers.
- Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study.
- Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
- Identification of vascular progenitor cells in pulmonary arteries of patients with chronic obstructive pulmonary disease.
- PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.
- Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling.
- Left atrial radiofrequency ablation during mitral valve surgery for continuous atrial fibrillation: a randomized controlled trial.
- A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
- High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
- Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
- Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients.
- 3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator.
- Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists.
- Aplysamine-1 and related analogs as histamine H3 receptor antagonists.
- Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
- Expression of procollagen C-proteinase enhancer-1 in the remodeling rat heart is stimulated by aldosterone.
- A free radical scavenger but not FGF-2-mediated angiogenic therapy rescues myonephropathic metabolic syndrome in severe hindlimb ischemia.
- Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study.
- Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
- Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA).
- WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE).
- 3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa.
- N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: synthesis, in vitro activity, and molecular modeling studies.
- Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.
- Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias.
- Enalapril preserves sinus node function in a canine atrial fibrillation model induced by rapid atrial pacing.
- The mechanism of atrial antiarrhythmic action of RSD1235.
- Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.
- Angiotensin II-induced changes of calcium sparks and ionic currents in human atrial myocytes: potential role for early remodeling in atrial fibrillation.
- Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta.
- Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors.
- Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.
- Soluble CD40 ligand levels in patients with hypertension.
- Anti-proliferative and anti-inflammatory effects of topical MAPK inhibition in arterialized vein grafts.
- AGI-1067: a novel vascular protectant for prevention of restenosis.
- High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
- A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi.
- Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 Next >